| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from BMY graph: Reciprocal relationship from TLSA graph: ill decide with respect to the covera… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
ill decide with respect to the coverage and reimbursement for our product candidates. Also, the containment of healthcare costs has become a priority of federal, state and foreign governments, and th… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
ill decide with respect to the coverage and reimbursement for our product candidates. Also, the containment of healthcare costs has become a priority of federal, state and foreign governments, and th… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from TLSA graph: ill decide with respect to the co… |
| CRDF |
Cardiff Oncology, Inc. |
72%
|
Reciprocal relationship from CRDF graph: Reciprocal relationship from TLSA graph: or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 20… |
| CRDF |
Cardiff Oncology, Inc. |
72%
|
or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 2016, Cardiff Oncology, Inc. from December 2005 until June 2022 and Okyo Pharma Ltd … |
| HEPA |
Hepion Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from HEPA graph: Reciprocal relationship from TLSA graph: or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 20… |
| HEPA |
Hepion Pharmaceuticals, Inc. |
72%
|
or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 2016, Cardiff Oncology, Inc. from December 2005 until June 2022 and Okyo Pharma Ltd … |
| MANU |
Manchester |
72%
|
Reciprocal relationship from MANU graph: Reciprocal relationship from TLSA graph: Reciprocal relationship from MANU graph: Reciprocal relationship from TLSA graph: or of Hepion Pharmaceuticals, Inc. … |
| MANU |
Manchester |
72%
|
or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actavia Life Sciences, Inc. since September 2016, Cardiff Oncology, Inc. from December 2005 until June 2022 and Okyo Pharma Ltd … |
| OKYO |
OKYO Pharma Limited |
72%
|
Reciprocal relationship from OKYO graph: Reciprocal relationship from TLSA graph: The Group has control when it can demonstrate all of the following: (a) power over the investee; (b) exposure, or rig… |
| OKYO |
OKYO Pharma Limited |
72%
|
The Group has control when it can demonstrate all of the following: (a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the abili… |
| SIGA |
SIGA Technologies, Inc. |
72%
|
currency. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from … |
| SIGA |
SIGA Technologies, Inc. |
72%
|
Reciprocal relationship from SIGA graph: Reciprocal relationship from TLSA graph: currency. Foreign currency transactions are translated into the functional currency using exchange rates prevailing a… |
| ACCUSTEM-SCIENCES-INC |
ACCUSTEM-SCIENCES-INC |
62%
|
he 6-month period. In October 2023 the loan was converted to an investment in OKYO with 20 % interest. The principal of $ 2,000 k plus accrued interest of $ 1,150 k were converted into 2,100,000 Ordi… |
| ACCUSTEM-SCIENCES-INC-GROUP |
ACCUSTEM-SCIENCES-INC-GROUP |
62%
|
s which are summarized below. Market risk Market risk encompasses three types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for manag… |
| ACUT |
AccuStem Sciences, Inc. |
62%
|
Reciprocal relationship from ACUT graph: Reciprocal relationship from TLSA graph: he 6-month period. In October 2023 the loan was converted to an investment in OKYO with 20 % interest. The principal … |
| FINANCIAL-COMMITMENTS-THE-GROUP |
FINANCIAL-COMMITMENTS-THE-GROUP |
62%
|
he 6-month period. In October 2023 the loan was converted to an investment in OKYO with 20 % interest. The principal of $ 2,000 k plus accrued interest of $ 1,150 k were converted into 2,100,000 Ordi… |
| GROUP-THE-GROUP |
GROUP-THE-GROUP |
62%
|
l and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present value at a pre-tax discount rate. Deferred Income The trea… |
| OKYO-PHARMA-LTD |
OKYO-PHARMA-LTD |
62%
|
he 6-month period. In October 2023 the loan was converted to an investment in OKYO with 20 % interest. The principal of $ 2,000 k plus accrued interest of $ 1,150 k were converted into 2,100,000 Ordi… |
| OPERATING-LOSS-THE-GROUP |
OPERATING-LOSS-THE-GROUP |
62%
|
l and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present value at a pre-tax discount rate. Deferred Income The trea… |
| POUND-STERLING-THE-GROUP |
POUND-STERLING-THE-GROUP |
62%
|
s which are summarized below. Market risk Market risk encompasses three types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for manag… |
| WOMEN-S-HOSPITAL-INC |
WOMEN-S-HOSPITAL-INC |
62%
|
ill decide with respect to the coverage and reimbursement for our product candidates. Also, the containment of healthcare costs has become a priority of federal, state and foreign governments, and th… |
